CN101028277A - Anti-cancer effect of Ezhang saponin and its use in preparation of anti-cancer agent - Google Patents

Anti-cancer effect of Ezhang saponin and its use in preparation of anti-cancer agent Download PDF

Info

Publication number
CN101028277A
CN101028277A CN 200710051898 CN200710051898A CN101028277A CN 101028277 A CN101028277 A CN 101028277A CN 200710051898 CN200710051898 CN 200710051898 CN 200710051898 A CN200710051898 A CN 200710051898A CN 101028277 A CN101028277 A CN 101028277A
Authority
CN
China
Prior art keywords
saponin
anticarcinogen
preparation
anemone
flaccid anemone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN 200710051898
Other languages
Chinese (zh)
Inventor
韩林涛
黄俊英
郑启兵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Han Lintao
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN 200710051898 priority Critical patent/CN101028277A/en
Publication of CN101028277A publication Critical patent/CN101028277A/en
Pending legal-status Critical Current

Links

Images

Landscapes

  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

An anticancer function of the goosefoot herb's saponin and the application of said goosefoot herb's saponin in preparing the medicine for preventing and treating cancers are disclosed.

Description

The antitumaous effect of flaccid anemone saponin and the application in the preparation anticarcinogen thereof
Technical field
The present invention relates to the antitumaous effect and the application thereof of flaccid anemone saponin.
Background technology
Flaccid anemone (Anemone flaccida Fr.Schmidt) is Ranunculaceae Anemone (Anemone L.) perennial plant.This platymiscium has about 150 kinds approximately, and all there is distribution different continents, and China has 54 kinds, and except that Hainan Province, all there is distribution other each province, and wherein flaccid anemone has distribution widely in western part, Hubei Province.This platymiscium can be made medicinal have Radde Anemone Rhizome (A.raddeana), flaccid anemone (A.flaccida), Herba Veronicastri Sibirici (A.rivularis) and wait several, how to be used as medicine with root or rhizome, has effects such as wind-damp dispelling, subduing swelling and detoxicating.As " treating rheumatism Chinese medicine preparation and preparation and application " (patent No. 200510018364.3), it forms effective ingredient: 3-O-α-L-pyrans rhamnose (1 → 2)-β-D-xylopyranose-oleanolic acid-28-O-α-L-pyrans rhamnose (1 → 4)-β-D-Glucopyranose. (1 → 6)-β-D-pyranglucoside, called after Rhizoma Anemones flaccidae saponin W 3, molecular formula are C 59H 96O 25, be used for the treatment of rheumatism.
Summary of the invention
The objective of the invention is at above-mentioned present situation, aim to provide the antitumaous effect and the application in the preparation anticarcinogen thereof of flaccid anemone saponin.
The implementation of the object of the invention is, the antitumaous effect of flaccid anemone saponin, and chemical structural formula is
Figure A20071005189800041
The flaccid anemone saponin in R1, saponins compound that the R2 substituent group is different, as 3-O-beta d glucopyranosiduronic acid-oleanolic acid-28-O-α-L-pyrans rhamnose (1 → 4)-β-D-Glucopyranose. (1 → 6)-β-D-pyranglucoside, molecular formula C 54H 86O 233-O-beta d glucopyranosiduronic acid-oleanolic acid-28-O-β-D-Glucopyranose. (1 → 6)-β-D-pyranglucoside, molecular formula C 48H 76O 193-O-α-L-pyrans rhamnose (1 → 2) β-D-glucose-oleanolic acid-28-O-α-L-pyrans rhamnose (1 → 4)-β-D-Glucopyranose. (1 → 6)-β-D-pyranglucoside, molecular formula C 58H 94O 253-O-α-L-pyrans rhamnose (1 → 2) α-L-arabopyranose-oleanolic acid-28-O-α-L-pyrans rhamnose (1 → 4)-β-D-Glucopyranose. (1 → 6)-β-D-pyranglucoside, molecular formula C 59H 96O 253-O-α-L-pyrans rhamnose (1 → 2) β-D-xylopyranose-oleanolic acid-28-O-α-L-pyrans rhamnose (1 → 4)-β-D-Glucopyranose. (1 → 6)-β-D-pyranglucoside, molecular formula C 59H 96O 23The energy inducing apoptosis of tumour cell has inhibitory action to tumor cell.
The application of flaccid anemone saponin in the preparation anticarcinogen, chemical structural formula is
Figure A20071005189800051
The flaccid anemone saponin in the different saponins compound of R1, R2 substituent group prepare anticarcinogen with the dosage form excipient of solid or liquid form, R1 in the flaccid anemone saponin in the anticarcinogen, the saponins compound adult oral dose that the R2 substituent group is different are the 1-50mg/60kg body weight.
Anticarcinogen once a day or several times is preferably 3-15mg/ days/60kg body weight.
Description of drawings
The saponins compound that Fig. 1 is R1 in the flaccid anemone, the R2 substituent group is different is induced HeLa Cells apoptotic effect design sketch
Fig. 2 is that the different saponins compound of R1 in the flaccid anemone, R2 substituent group is expressed impact effect figure to Caspase-3 in the HeLa Cells
The specific embodiment
The chemical structural formula of flaccid anemone saponin of the present invention is
Figure A20071005189800052
R1, the flaccid anemone saponins compound that the R2 substituent group is different have following several:
1.3-O-beta d glucopyranosiduronic acid-oleanolic acid-28-O-α-L-pyrans rhamnose (1 → 4)-β-D-Glucopyranose. (1 → 6)-β-D-pyranglucoside, R1, R2 substituent group are respectively glcA, glc (6-1) glc (4-1) rha, molecular formula C 54H 86O 23, spectral data
Mp：217～218℃(dec)
IRv max KBr：3421(-OH)，1733(C＝O)，1613(C＝C)，1480，1385，1260，1032
UVλ max MeOH nm：206
ESI-MS m/z：1102[M] -，632，456
1H-NMR(C 5D 5N+D 2O)δ：0.77(3H，s，CH 3)、0.83(3H，s，CH 3)、0.85(3H，s，CH 3)、0.94(3H，s，CH 3)、1.01(3H，s，CH 3)、1.19(3H，s，CH 3)、1.24(3H，s，CH 3)，1.63(3H，d，J＝6.18Hz)
δ：4.84(1H，d，J＝9.3Hz)，4.93(1H，d，J＝7.8Hz)，5.76(1H，br.s)，6.16(1H，d，J＝8.11Hz)
2.3-O-beta d glucopyranosiduronic acid-oleanolic acid-28-O-β-D-Glucopyranose. (1 → 6)-β-D-pyranglucoside, R1, R2 substituent group are respectively glcA, glc (6-1) glc, molecular formula C 48H 76O 19, spectral data
Mp：207～208℃(dec)
IRv max KBr：3406(-OH)，1732(C＝O)，1611(C＝C)，1480，1385，1260，1029
UVλ max MeOH nm：206
ESI-MS m/z：956[M] -，632，456
1H-NMR(C 5D 5N+D 2O)δ：0.76(3H，s，CH 3)、0.82(3H，s，CH 3)、0.84(3H，s，CH 3)、0.94(3H，s，CH 3)、1.02(3H，s，CH 3)、1.19(3H，s，CH 3)、1.24(3H，s，CH 3)；
δ：4.85(1H，d，J＝8.0Hz)，4.95(1H，d，J＝8.0Hz)，6.17(1H，d，J＝8.8Hz)
3.3-O-α-L-pyrans rhamnose (1 → 2) β-D-glucose-oleanolic acid-28-O-α-L-pyrans rhamnose (1 → 4)-β-D-Glucopyranose. (1 → 6)-β-D-pyranglucoside, R1, R2 substituent group are respectively glc (2-1) rha, glc (6-1) glc (4-1) rha, C 58H 94O 25, spectral data
Mp：215～218℃(dec)
IRv max KBr：3100-3600，1063，2940，1735，1635
UVλ max MeOH nm：209
ESI-MS m/z：1233[M-H] -，1087，763，469，455
1H-NMR(C 5D 5N)δ：0.82(3H，s，CH 3)，0.84(3H，s，CH 3)，0.85(3H，s，CH 3)，1.05(3H，s，CH 3)1.16(3H，s，CH 3)，1.19(3H，s，CH 3)，1.21(3H，s，CH 3)，
δ：1.65(3H，d，J＝6.18Hz)，5.35(1H，br.s)6.55(1H，br.s)，6.21(1H，d，J＝7.9Hz)，5.83(1H，br.s)，4.96(1H，d，J＝8.2Hz)4.82(1H，d，J＝6.5Hz)
4.3-O-α-L-pyrans rhamnose (1 → 2) α-L-arabopyranose-oleanolic acid-28-O-α-L-pyrans rhamnose (1 → 4)-β-D-Glucopyranose. (1 → 6)-β-D-pyranglucoside, R1, R2 substituent group are respectively glc (2-1) rha, glc (6-1) glc (4-1) rha, C 58H 96O 25, spectral data
Mp：208～210℃(dec)
IRv max KBr：3413(-OH)，1734(C＝O)，1648(C＝C)，1458，1387，1262，1231，1085
UVλ max MeOH nm：206
ESI-MS m/z：1227.5[M+Na] +，1081.5，949.5，757.4
1H-NMR(C 5D 5N)δ：0.87(9H，m，3×CH3)，1.06(3H，s，CH3)，1.07(3H，s，CH3)，1.15(3H，s，CH3)，1.22(3H，s，CH3)，1.61(3H，d，J＝5.86Hz)，1.70(3H，d，J＝5.86Hz)
δ：4.87(1H，d，J＝4.89Hz)，4.97(1H，d，J＝8.3Hz)，5.85(1H，br.s)，6.14(1H，d，br.s)，6.23(1H，d，J＝7.81Hz)
5.3-O-α-L-pyrans rhamnose (1 → 2) β-D-xylopyranose-oleanolic acid-28-O-α-L-pyrans rhamnose (1 → 4)-β-D-Glucopyranose. (1 → 6)-β-D-pyranglucoside, R1, R2 substituent group are respectively glc (2-1) rha, glc (6-1) glc (4-1) rha, C 58H 96O 25, spectral data
Mp：208～210℃(dec)
IRv max KBr：3408(-OH)，1735(C＝O)，1642(C＝C)，1480，1387，1260，1232，1037
UVλ max MeOHnm：205
ESI-MS m/z：1203[M-H] -，733，469
1H-NMR(C 5D 5N)δ：0.87(9H，m，3×CH 3)，1.08(3H，s，CH 3)，1.18(3H，s，CH 3)，1.22(3H，s，CH3)，1.23(3H，s，CH3)，1.69(3H，d，J＝4.88Hz)，1.70(3H，d，J＝5.37Hz)
δ：4.82(1H，d，J＝7.3Hz)，4.98(1H，d，J＝7.8Hz)，5.85(1H，br.s)，6.23(1H，d，J＝7.82Hz)，6.53(1H，br.s，C-5-CH3 of Rha)
The flaccid anemone saponin prepares anticarcinogen with the dosage form excipient of solid or liquid form, the dosage form excipient of solid or liquid form is excipient commonly used, and the dosage of excipient should satisfy R1 in the flaccid anemone saponin in the anticarcinogen, saponins compound adult oral dose that the R2 substituent group is different is the 1-50mg/60kg body weight.Anticarcinogen once a day or several times is preferably 3-15mg/ days/60kg body weight.Dosage form has peroral dosage form, injection, topical dosage form;
Peroral dosage form has powder, tablet, suspension, Emulsion, capsule, granule, lozenge, pill, spirit, syrup or limonada;
The topical dosage form has ointment, solid, suspension, powder, paste, suppository, aerosol, paste, liniment, lotion, enema or Emulsion.
Spendable, the excipient of known solid or liquid form all can be used for anticarcinogen of the present invention,
The excipient of powder and other oral powder has one or more in lactose, crystalline cellulose, starch, dextrin, calcium phosphate, calcium carbonate, synthetic and natural aluminium dioxide, magnesium oxide, Aluminium Hydroxide, magnesium stearate, the sodium bicarbonate;
Excipient in the topical powder has one or more in zinc oxide, Pulvis Talci, starch, Kaolin, borate powder, zinc stearate, magnesium stearate, magnesium carbonate, winnofil, bismuth subgallate, the potassium sulfate aluminium powder;
The excipient of liquid preparation has one or more in water, glycerol, propylene glycol, sweet taste syrup, ethanol, fatty oil, Polyethylene Glycol, the sorbitol;
That the excipient of ointment has is cured through mixing-in fat, fatty oil, lanoline, vaseline, glycerol, wax, Japan, paraffin, sulphuric acid paraffin, resin, higher alcohol, plastics, glycols, water or surfactant and the hydrophobic or hydrophilic matrix made comprises oily molten base, water-soluble base and the base that suspends.
Enumerate formulation Example of the present invention below:
Example 1: it is that mix homogeneously is used the tablet machine tabletting in 1 the flaccid anemone saponin that the mixture of lactose, crystalline cellulose and 1% magnesium stearate is added to 30mg R1, R2 substituent group, tablet.
Example 2: it is that mix homogeneously is used the tablet machine tabletting in 2 the flaccid anemone saponin that the mixture of lactose, crystalline cellulose and 1% magnesium stearate is added to 30mg R1, R2 substituent group, tablet.
Example 3: it is that mix homogeneously is used the tablet machine tabletting in 3 the flaccid anemone saponin that the mixture of lactose, crystalline cellulose and 1% magnesium stearate is added to 30mg R1, R2 substituent group, tablet.
Example 4: it is that mix homogeneously is used the tablet machine tabletting in 4 the flaccid anemone saponin that the mixture of lactose, crystalline cellulose and 1% magnesium stearate is added to 30mg R1, R2 substituent group, tablet.
Example 5: it is that mix homogeneously is used the tablet machine tabletting in 5 the saponin that the mixture of lactose, crystalline cellulose and 1% magnesium stearate is added to 30mg R1, R2 substituent group, tablet.
Example 6: under the sterile working, be that 1 the flaccid anemone saponin and the solution of Spheron MD 30/70 (polysorbit 80) pour into sterile vials with 15mg R1, R2 substituent group, remove moisture after, obtain injection preparation.
Example 7: under the sterile working, be that 2 the flaccid anemone saponin and the solution of Spheron MD 30/70 (polysorbit 80) pour into sterile vials with 15mg R1, R2 substituent group, remove moisture after, obtain injection preparation.
Example 8: under the sterile working, be that 3 the flaccid anemone saponin and the solution of Spheron MD 30/70 (polysorbit 80) pour into sterile vials with 15mg R1, R2 substituent group, remove moisture after, obtain injection preparation.
Example 9: under the sterile working, be that 4 the flaccid anemone saponin and the solution of Spheron MD 30/70 (polysorbit 80) pour into sterile vials with 15mg R1, R2 substituent group, remove moisture after, obtain injection preparation.
Example 10: under the sterile working, be that 5 the flaccid anemone saponin and the solution of Spheron MD 30/70 (polysorbit 80) pour into sterile vials with 15mg R1, R2 substituent group, remove moisture after, obtain injection preparation.
The applicant has done the test of flaccid anemone saponine anti-tumor:
Experiment 1, flaccid anemone saponin are to the anti-tumor activity of human cervical carcinoma cell strain HeLa
A. experimental technique
Human cervical carcinoma cell strain HeLa is adopted in this experiment, and the phase cell of taking the logarithm is made cell suspension, and being diluted to concentration is 2.5 * 10 3-50 * 10 3/ mL is inoculated in 96 well culture plates, every hole 200 μ L, and the 24h hypsokinesis goes out culture fluid, adding contains variable concentrations R1, the R2 substituent group is the culture fluid of the flaccid anemone saponin of 1-5, and final concentration is 50,20,5,0.5 μ mol/L adds PBS and be blank in culture fluid, every sample is all established 4 holes.Control wells and zeroing hole add 200 μ L culture fluid.24h adds MTT solution 20 μ L after dosing, continues to cultivate, and carefully removes culture fluid, adds 200 μ LDMSO, measures each hole A value on microplate reader, and the mensuration wavelength is 570nm.By formula suppression ratio (IR): IR (%)=(1-dosing holes average A value/control wells average A value) * 100% calculates suppression ratio.Draw amount effect curve according to the suppression ratio under the variable concentrations, calculate IC thus 50Value.Table 1 has shown experimental result
Table 1
Sample Hela cell IC 50(μmmol/L)
Contrast 12345 / 15.22 a 16.34 4.28 3.99 1.21
A estimates: strong active (IC 50＜0.1 μ molL-1), active (0.1 μ molL-1＜IC 50＜1 μ molL-1), weak activity (1 μ molL-1＜IC 50＜20 μ molL-1), non-activity (IC 50＞20 μ molL-1), substituent R 1, R2 are having the greatest impact of 5 flaccid anemone saponin pair cell apoptosis, secondly are 4,3,1,2 flaccid anemone saponin for R1, R2 substituent group.
Experiment 2, flow cytometer detect R1, the R2 substituent group is the influence of the flaccid anemone saponin pair cell apoptosis of 1-5
A. experimental technique
Go down to posterity after the HeLa Cells growth 24h that cultivates, the flaccid anemone saponin that adds R1, R2 substituent group respectively and be 1-5 continues to cultivate 12h, and final concentration is 0.05mg/mL, and negative control group adds the equivalent solvent.Take out cell then after PBS cleans, fix with 70% ice ethanol.Centrifugal before detecting, after the PBS cleaning, abandon supernatant.The back adds 1mL dyeing liquor (containing PI 0.1mg/mL, RNase 0.1mg/mL, PBS preparation), and room temperature lucifuge 20min goes up machine after crossing 300 order nylon wires, use the CELLQuest software analysis, the ratio of mensuration apoptotic cell.
B. experimental result sees Table 2 and Fig. 2,
Table 2
Sample Apoptosis rate (%)
Contrast 12345 0.28 7.23 4.65 10.01 10.82 23.25
Experimental result discloses each saponin demonstration and induces the HeLa Cells apoptotic effect, is the mechanism of action of its anti-tumor activity.
Fig. 2 shows that the flaccid anemone saponin is followed successively by R1, R2 substituent group 5 (F), 4 (E) to human cervical carcinoma cell HeLa apoptotic effect size,, 3 (D), 1 (B), 2 (C).
Experimental example 3, the influence that the flaccid anemone saponin is expressed human cervical carcinoma cell Caspase-3
A. experimental technique
Cell climbing sheet preparation: when the Hela cell covers with culture bottle 80%, clean reuse 0.25% trypsin room temperature digestion 2-3min with PBS, with softly piping and druming repeatedly of suction pipe, cell is dispelled, be inoculated in 6 orifice plates that preset coverslip, it is the saponin 1-5 of 50 μ g/mL that adherent back adds final concentration of cells, negative control group adds the equivalent solvent, take out coverslip behind the conventional cultivation 24h, fix, carry out cellular immunization with 4% Polyethylene Glycol, groupization dyeing detects the proteic expression of caspase-3.
Concrete steps: get fixed cell climbing sheet, wash 2 times with PBS, cold wind dries up; 0.1%Triton-X100 is hatched 1 time, and wash 3 times with PBS the back; 3%H 2O 2Hatch with the blocking-up endogenous peroxydase, PBS shakes and washes 3 times afterwards; Drip normal goats serum confining liquid, in wet box, 37 ℃ of insulations to eliminate unspecific staining, discard unnecessary liquid, do not wash;
Drip one anti-(caspase-3 rat IgG) of dilution in 1: 100, in wet box, 4 ℃ are spent the night, and PBS shakes and washes 3 times, each 3min; Drip the anti-IgG of biotinylated goat, in wet box, 37 ℃ of insulations, PBS shakes and washes 3 times; Drip reagent SABC, in wet box, 37 ℃ of insulations, PBS shakes and washes 3 times;
DAB dyeing: use DAB colour reagent box, get the 1ml distilled water, add each one of A in the test kit, B, C reagent, add to coverslip behind the mixing, color development at room temperature, mirror is the control reaction down, back distillation washing 2 times;
Haematoxylin is redyed (the nucleus lining dyes): immerse brazilwood extract dyeing liquid, and washing from the beginning, the persalt alcoholic solution is to break up multiple indigo plant, washing rapidly;
Dehydration step by step: cross 75%, 95%, 100% dehydrated alcohol;
Transparent: as to cross xylene solution 3 times;
Mounting: will have one of cell to face down, and use the resinene mounting.
Microscopically is observed: every smear is got 10 visuals field at random, 300～500 cells of each visual field counting.Count Caspase-3 immuning positive cell number and negative cells number respectively, carry out statistical analysis.Pale brown color or brown occurring in cell membrane and cytoplasm, to be that Caspase-3 expresses positive, and nucleus is dyed blue color.
B. experimental result sees Table 3 and shown in Figure 3, and experimental result discloses each saponin demonstration and induces HeLa Cells caspase-3 high expressed, and further conclusive evidence is that the mechanism of action of its anti-tumor activity is apoptosis-induced effect.
Table 3
Sample Caspase3 expression rate (%)
Contrast 12345 7.8 15.8 9.7 22.1 24.5 33.8
Fig. 3. the flaccid anemone saponin influences the order size to Caspase-3 expression activity in the HeLa Cells and is followed successively by R1, R2 substituent group 5 (F), 4 (E), 3 (D), 1 (B), 2 (C).Amplification * 400.
Can see that from The above results substituent R 1, R2 are that the flaccid anemone saponin of 1-5 has antitumor action, comprise and suppress tumor growth, inducing apoptosis of tumour cell and improve Caspase-3 expressional function in the tumor cell.
In some experiments with rat and mice, R1, R2 substituent group are that the toxicity of the flaccid anemone saponin of 1-5 is bordering on and can ignores, and the stability of formulation of each formulation Example is qualified.

Claims (9)

1, the antitumaous effect of flaccid anemone saponin is characterized in that chemical structural formula is
Figure A2007100518980002C1
The flaccid anemone saponin in R1, saponins compound that the R2 substituent group is different, as 3-O-beta d glucopyranosiduronic acid-oleanolic acid-28-O-α-L-pyrans rhamnose (1 → 4)-β-D-Glucopyranose. (1 → 6)-β-D-pyranglucoside, molecular formula C 54H 86O 233-O-beta d glucopyranosiduronic acid-oleanolic acid-28-O-β-D-Glucopyranose. (1 → 6)-β-D-pyranglucoside, molecular formula C 48H 76O 193-O-α-L-pyrans rhamnose (1 → 2) β-D-glucose-oleanolic acid-28-O-α-L-pyrans rhamnose (1 → 4)-β-D-Glucopyranose. (1 → 6)-β-D-pyranglucoside, molecular formula C 58H 94O 253-O-α-L-pyrans rhamnose (1 → 2) α-L-arabopyranose-oleanolic acid-28-O-α-L-pyrans rhamnose (1 → 4)-β-D-Glucopyranose. (1 → 6)-β-D-pyranglucoside, molecular formula C 59H 96O 253-O-α-L-pyrans rhamnose (1 → 2) β-D-xylopyranose-oleanolic acid-28-O-α-L-pyrans rhamnose (1 → 4)-β-D-Glucopyranose. (1 → 6)-β-D-pyranglucoside, molecular formula C 59H 96O 23The energy inducing apoptosis of tumour cell has inhibitory action to tumor cell.
2, the application of the described flaccid anemone saponin of claim 1 in the preparation anticarcinogen is characterized in that chemical structural formula is
Figure A2007100518980002C2
The flaccid anemone saponin in the different saponins compound of R1, R2 substituent group prepare anticarcinogen with the dosage form excipient of solid or liquid form, R1 in the flaccid anemone saponin in the anticarcinogen, the saponins compound adult oral dose that the R2 substituent group is different are the 1-50mg/60kg body weight.
3, the application of flaccid anemone saponin according to claim 2 in the preparation anticarcinogen is characterized in that dosage form has peroral dosage form, injection or topical dosage form,
4, the application of flaccid anemone saponin according to claim 3 in the preparation anticarcinogen is characterized in that peroral dosage form has powder, tablet, suspension, Emulsion, capsule, granule, lozenge, pill, spirit, syrup or limonada.
5, the application of flaccid anemone saponin according to claim 3 in the preparation anticarcinogen is characterized in that the topical dosage form has ointment, solid, suspension, powder, paste, suppository, aerosol, paste, liniment, lotion, enema or Emulsion.
6, flaccid anemone saponin according to claim 2 is in the application of preparation in the anticarcinogen, and the excipient that it is characterized in that powder and other oral powder has one or more in lactose, crystalline cellulose, starch, dextrin, calcium phosphate, calcium carbonate, synthetic and natural aluminium dioxide, magnesium oxide, Aluminium Hydroxide, magnesium stearate, the sodium bicarbonate;
7, flaccid anemone saponin according to claim 2 is in the application of preparation in the anticarcinogen, it is characterized in that excipient in the topical powder has one or more in zinc oxide, Pulvis Talci, starch, Kaolin, borate powder, zinc stearate, magnesium stearate, magnesium carbonate, winnofil, bismuth subgallate, the potassium sulfate aluminium powder;
8, flaccid anemone saponin according to claim 2 is in the application of preparation in the anticarcinogen, and the excipient that it is characterized in that liquid preparation has one or more in water, glycerol, propylene glycol, sweet taste syrup, ethanol, fatty oil, Polyethylene Glycol, the sorbitol.
9, the application of flaccid anemone saponin according to claim 2 in the preparation anticarcinogen, that the excipient that it is characterized in that ointment has is cured through mixing-in fat, fatty oil, lanoline, vaseline, glycerol, wax, Japan, paraffin, sulphuric acid paraffin, resin, higher alcohol, plastics, glycols, water or surfactant and the hydrophobic or hydrophilic matrix made comprises oily molten base, water-soluble base and the base that suspends.
CN 200710051898 2007-04-17 2007-04-17 Anti-cancer effect of Ezhang saponin and its use in preparation of anti-cancer agent Pending CN101028277A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 200710051898 CN101028277A (en) 2007-04-17 2007-04-17 Anti-cancer effect of Ezhang saponin and its use in preparation of anti-cancer agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 200710051898 CN101028277A (en) 2007-04-17 2007-04-17 Anti-cancer effect of Ezhang saponin and its use in preparation of anti-cancer agent

Publications (1)

Publication Number Publication Date
CN101028277A true CN101028277A (en) 2007-09-05

Family

ID=38713928

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 200710051898 Pending CN101028277A (en) 2007-04-17 2007-04-17 Anti-cancer effect of Ezhang saponin and its use in preparation of anti-cancer agent

Country Status (1)

Country Link
CN (1) CN101028277A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102250190A (en) * 2011-05-30 2011-11-23 江西本草天工科技有限责任公司 Oleanolic saponin derivative, preparation method of salt thereof and application of derivative
CN102552129A (en) * 2012-03-12 2012-07-11 广州康和药业有限公司 Anemone flaccida saponin W3 injection and preparation method thereof
CN102552441A (en) * 2012-03-12 2012-07-11 广州康和药业有限公司 Flaccid anemone rhizome extract soft capsule and preparation method thereof
CN103926121A (en) * 2014-04-10 2014-07-16 首都医科大学 Preparation method of cell slide

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102250190A (en) * 2011-05-30 2011-11-23 江西本草天工科技有限责任公司 Oleanolic saponin derivative, preparation method of salt thereof and application of derivative
CN102250190B (en) * 2011-05-30 2013-05-15 江西本草天工科技有限责任公司 Preparation method Oleanolic saponin derivative and salts thereof, and application thereof
CN102552129A (en) * 2012-03-12 2012-07-11 广州康和药业有限公司 Anemone flaccida saponin W3 injection and preparation method thereof
CN102552441A (en) * 2012-03-12 2012-07-11 广州康和药业有限公司 Flaccid anemone rhizome extract soft capsule and preparation method thereof
CN103926121A (en) * 2014-04-10 2014-07-16 首都医科大学 Preparation method of cell slide

Similar Documents

Publication Publication Date Title
CN101028277A (en) Anti-cancer effect of Ezhang saponin and its use in preparation of anti-cancer agent
CN1762465A (en) Rhinitis gel, its preparation method and quality control technology
CN1887270A (en) Nanometer berberine hydrochloride emulsion and its prepn process
CN1823976A (en) External use medicine for relieving itch
CN1895296A (en) Inspection for lucid ganoderma product oral preparation quality
CN1583134A (en) Effervescent tablets of taraxacum mongolicum and their preparation
CN1281616C (en) Compound extracted from xanthoceras sorbifolia shells and stems, extraction method and application
CN1189176C (en) Astragalus root methyl-glycoside composition and preparation method
CN1827631A (en) Novel tyrosinase inhibitor and use thereof
CN105106327A (en) Process for extracting total flavones of red-knees herb by adopting enzymolysis-ultrasonic coupling method
CN1303098C (en) Pseudo portulaca oleracea saponin compound, total sapon in and its application in medicine
CN106074499A (en) The application in medicine of a kind of Crow alkane type diterpene-kind compound
CN113116972B (en) Application of goldhair hedyotis herb extract in preparing anti-oxidation and anti-tumor medicines
CN1293901C (en) Chinese medicinal preparation for preventing herpes virus and preparing method thereof
CN115073484A (en) Method for extracting and separating active ingredients of Zhuang medicine Tou Gu Xiang
CN1252078C (en) Method for extracting total aglycone of Macrotys and its antitumour action
CN100341888C (en) Anticancer new compound of Xiacaogan I, preparation method, and application in pharmacy
CN1714840A (en) Chinese medicine composition for stopping itching and its preparing method
CN104288158B (en) Method for preparing skin cleaning liquid containing tanshinone
CN102631441B (en) Separation and purification method of total saponins of sanguisorba officinalis
CN1839903A (en) Pharmaceutical composition containing glabrous sarcandra herb extract and its uses
CN1283391A (en) Extracted liquor for disinfection
CN102100692A (en) Prenylflavanone compound and use thereof in preparation of anti-tumor medicaments
CN1634431A (en) Drop pills containing honeysuckle flower and radix Scutellariae extract for treating upper respiratory tract infection
CN1884246A (en) Method for extracting diaryl heptane compounds from galangas

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: HAN LINTAO

Free format text: FORMER OWNER: HAN LINTAO; APPLICANT

Effective date: 20080111

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20080111

Address after: Hubei province Wuhan city Hongshan District Huangjiahu Silut 1, Hubei College of Traditional Chinese Medicine School of medicine in post encoding: 430065

Applicant after: Han Lintao

Address before: Zip code, Hubei College of Traditional Chinese Medicine, Silut 1, Huang Jia Hu, Hongshan District, Wuhan, Hubei, China: 430074

Applicant before: Han Lin Tao

Co-applicant before: Huang Junying

Co-applicant before: Zheng Qibing

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20070905